CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

Rhea-AI Summary

CytoSorbents (NASDAQ: CTSO) announced its upcoming scientific presentations at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Copenhagen, October 8-11, 2025. The event will showcase groundbreaking data for their blood purification technologies CytoSorb® and DrugSorb™-ATR in cardiac surgery applications.

Two significant presentations will be featured: The first randomized trial results of DrugSorb-ATR for removing direct oral anticoagulants during urgent cardiac surgery, and a real-world study showing CytoSorb's effectiveness in reducing bleeding complications in acute coronary syndrome patients undergoing CABG surgery. Additionally, a company-sponsored lunch symposium will discuss hemoadsorption as a safety net in cardiac surgery.

PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting, the world's largest gathering for the global cardiothoracic community, taking place October 8–11, 2025 in Copenhagen, Denmark. The meeting is expected to attract more than 5,000 attendees from around the world.

CytoSorbents' new data at EACTS further validates the vital role of CytoSorb® and DrugSorb™-ATR in cardiac surgery,

CytoSorbents' presence at EACTS will feature two high-profile scientific presentations of original data and a Company-sponsored lunch symposium highlighting the expanding role of its sorbent hemoperfusion technologies as a safety net in cardiac surgery.

Dr. Daniel Wendt, Vice President of Cardiovascular Medical Affairs at CytoSorbents stated, "We are excited to share new data at EACTS that further validates the important role of CytoSorb® and DrugSorb™-ATR in cardiac surgery. From the first randomized trial results of DrugSorb-ATR in patients on DOACs, to real-world evidence in acute coronary syndrome (ACS) patients undergoing coronary artery bypass grafting (CABG) surgery, our technologies continue to demonstrate significant clinical impact that is helping to change the practice of cardiovascular medicine. We look forward to engaging with cardiac surgeons and thought leaders worldwide during this year's meeting."

Original Presentations – Thursday, October 9, 2025 | 8:30 -10:30 AM CET

Intraoperative Removal of Direct Oral Anticoagulants in Patients Undergoing Urgent Cardiothoracic Surgery

• Presenter:  Professor Richard Whitlock, McMaster University, Hamilton, Canada
• Significance:  This is the first randomized controlled trial data demonstrating that intraoperative use of DrugSorb™-ATR significantly reduces levels of direct oral anticoagulants (DOACs), such as Eliquis® (apixaban, Pfizer/Bristol Myers Squibb) and Xarelto® (rivaroxaban, Janssen/Bayer), compared to sham control in patients undergoing urgent cardiac surgery.

Dual Antiplatelet Therapy (DAPT) and Urgent CABG in Acute Coronary Syndrome (ACS): Impact of P2Y12 Inhibitor Choice & Intraoperative Hemoadsorption on Perioperative Bleeding: Comparative Real-World Analysis

• Presenter:  Professor Matthias Thielmann, Westerman Heart & Vascular Center, Essen, Germany
• Significance:  This real-world study demonstrates that among ACS patients undergoing urgent CABG, combining dual antiplatelet therapy (aspirin + ticagrelor) with intraoperative use of CytoSorb® is associated with highly significant reductions in severe bleeding complications compared with patients treated with aspirin + Plavix (clopidogrel) without CytoSorb.

CytoSorbents Sponsored Lunch Symposium – Friday, October 10, 2025 | 12:15 – 1:30 PM CET

Hemoadsorption as Safety Net in Cardiac Surgery: New Insights
Moderators: Professor Christian Hagl, Ludwig-Maximilians-University, Munich, Germany and Professor Thierry Folliguet, Henri Mondor Hospital, Paris, France

Symposium Topics Include:

"Can We Improve the Outcome of Endocarditis Patients?"

• Presenter: Professor Yeong-Hoon Choi, Kerckhoff Clinic, University of Giessen, Bad Nauheim, Germany
• "Why Should We Combine VA ECMO with Hemoadsorption in Cardiogenic Shock Patients?"
• Presenter: Professor Anna Mara Scandroglio, IRCCS San Raffaele Scientific Institute, Milan, Italy

"Removal of Antithrombotic Drugs – Evidence from the STAR-T RCT and the International STAR Registry"

• Professor Richard Whitlock, McMaster University, Hamilton, Canada

For more information on applications of CytoSorbents' technologies in cardiac surgery and ECMO, please visit: https://cytosorbents.com/cardiovascular/

For more information on applications in critical care, please follow these links: Turning the tide in sepsis and septic shock (Global sepsis webinar, presentation, white paper, blog), ARDS, liver failure, and rhabdomyolysis. 

Meanwhile, watch videos from healthcare providers from around the world who detail their first-hand experiences with CytoSorb in the treatment of critical and cardiac surgery illnesses in our "Voices Around the World" segment, found here.

CytoSorb is CE-mark approved in the E.U. and distributed in more than 70 countries globally as an extracorporeal cytokine adsorber and for the removal of bilirubin, myoglobin, and certain antithrombotic drugs. CytoSorb and DrugSorb-ATR are not yet approved or cleared in the U.S.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already found in hospitals (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure, and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis, as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with nearly 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first extracorporeal cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure to reduce inflammatory cytokines. CytoSorb is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others.

For more information, please visit the Company's website at https://ir.cytosorbents.com/ or follow us on Facebook and X. 

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to our ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, the ability to grow sales and cut costs, the outcome of the restructuring of our direct sales team and strategy in Germany, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

U.S. Company Contact: 
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com 

Investor Relations Contact:
Aman Patel, CFA & Adanna G. Alexander, PhD
ICR Healthcare ir@cytosorbents.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-showcase-pioneering-new-cardiac-surgery-data-in-key-applications-at-the-eacts-2025-annual-meeting-in-copenhagen-302569199.html

SOURCE Cytosorbents Corp

FAQ

When and where is CytoSorbents (CTSO) presenting at EACTS 2025?

CytoSorbents will present at the EACTS Annual Meeting in Copenhagen, Denmark from October 8-11, 2025. The event is expected to attract over 5,000 attendees globally.

What are the main studies CytoSorbents (CTSO) will present at EACTS 2025?

CytoSorbents will present two key studies: The first randomized trial of DrugSorb-ATR for removing direct oral anticoagulants in urgent cardiac surgery, and a real-world study of CytoSorb showing reduced bleeding complications in ACS patients undergoing CABG surgery.

What is the significance of CytoSorbents' DrugSorb-ATR trial results?

The trial demonstrates that DrugSorb-ATR significantly reduces levels of direct oral anticoagulants (like Eliquis® and Xarelto®) compared to sham control in patients undergoing urgent cardiac surgery.

What topics will be covered in CytoSorbents' lunch symposium at EACTS 2025?

The symposium will cover improving outcomes in endocarditis patients, combining VA ECMO with hemoadsorption in cardiogenic shock patients, and removal of antithrombotic drugs with evidence from the STAR-T RCT and International STAR Registry.